Hookipa Pharma raises $37.4 million

26 February 2019

Austria-based clinical stage biotech Hookipa Pharma, which is developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, says it has completed a $37.4 million series D financing.

The investment was led by Redmile Group with participation of additional new investors Invus and Samsara BioCapital, as well as a number of current investors.

The new funding will be primarily used to progress the clinical development of Hookipa’s lead development programs, HB-101, a prophylactic cytomegalovirus vaccine candidate, currently in a Phase II clinical trial in patients awaiting kidney transplantation, as well as HB-201 and HB-202, the company’s lead oncology product candidates, in development for the treatment of human papillomavirus-positive cancers. In addition, Hookipa plans to apply its arenavirus platform to develop additional novel immuno-oncology product candidates.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK